Novel biomarkers for prostate cancer including noncoding transcripts

American Journal of Pathology

Volumn 175, Issue 6, 2009, Pages 2264-2276

  Romanuik, Tammy L ^a   Ueda, Takeshi ^b   Le, Nhu ^a   Haile, Simon ^a   Yong, Theresa M K ^a   Thomson, Thomas ^a   Vessella, Robert L ^c   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CHIBA CANCER CENTER   (Japan)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN DEPOLYMERIZING FACTOR; ACTIN DEPOLYMERIZING FACTOR DESTRIN; ADAM 2 PROTEIN; ADAM PROTEIN; ANDROGEN; BIOLOGICAL MARKER; CELL PROTEIN; FOLLISTATIN LIKE DOMAIN 2; FOLLISTATIN RELATED PROTEIN; FRAGILE HISTIDINE TRIAD PROTEIN; MARCKS PROTEIN; MARCKSL 1 PROTEIN; MEMBRANE PROTEIN; MEMBRANE PROTEIN 30 A; MEMBRANE PROTEIN 66; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; NERVE CELL ADHESION MOLECULE 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN RELEASE; ARTICLE; BIOCHEMISTRY; CANCER DIAGNOSIS; CANCER PATIENT; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRON; LASER MICRODISSECTION; MALE; NUCLEOTIDE SEQUENCE; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RECURRENT DISEASE; SAMPLE; TISSUE SPECIFICITY;

EID: 73549107655     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080868     Document Type: Article

References (72)

1. Lilja H, Ulmert D, Vickers AJ: Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008, 8:268-278
2. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA, Jr.: Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 2006, 98:529-534
3. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B: Human prostate cancer risk factors. Cancer 2004, 101:2371-2490
4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 Ng per milliliter. N Engl J Med 2004, 350:2239-2246
5. Stamey TA, Yang N, Hay AR, Mcneal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909-916
6. Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK: Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 2007, 109:1689-1695
7. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999, 281:1591-1597
8. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM: Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-333
9. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL: Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007, 109:198-204
10. Crawford ED, Eisenberger MA, Mcleod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989, 321:419-424
11. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520
12. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512
13. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE: Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002, 168:995-1000
14. Quayle SN, Hare H, Delaney AD, Hirst M, Hwang D, Schein JE, Jones SJ, Marra MA, Sadar MD: Novel expressed sequences identified in a model of androgen independent prostate cancer. BMC Genomics 2007, 8:32
15. Sadar MD, Akopian VA, Beraldi E: Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Mol Cancer Ther 2002, 1:629-637
16. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD: Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific CDNA probes and libraries. Proc Natl Acad Sci USA 1996, 93:6025-6030
17. Lapointe J, Li C, Higgins JP, Van De Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, Demarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004, 101:811-816
18. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003, 63:4196-4203
19. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, Van Weerden WM, Bangma CH, Trapman J, Jenster G: Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006, 66:5012-5020
20. Geller J: Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol 1985, 12:28-35
21. Balk SP, Knudsen KE: AR. The cell cycle, and prostate cancer. Nucl Recept Signal 2008, 6:e001
22. Huggins C, Hodges C: Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 293-297
23. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T: Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 2004, 92:221-236
24. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 1983, 43:1809-1818
25. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979, 17:16-23
26. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978, 21:274-281
27. Sramkoski RM, Pretlow TG, 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999, 35:403-409
28. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, Von Eschenbach AC, Logothetis CJ: Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997, 3:2493-2500
29. Horwitz KB, Costlow ME, Mcguire WL: MCF-7: a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 1975, 26:785-795
30. Beilin J, Ball EM, Favaloro JM, Zajac JD: Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and nonprostate cell lines. J Mol Endocrinol 2000, 25:85-96
31. Sakr WA, Grignon DJ, Haas GP, Schomer KL, Heilbrun LK, Cassin BJ, Powell J, Montie JA, Pontes JE, Crissman JD: Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract 1995, 191:838-841
32. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA, Jr.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224
33. Beyer DC: The evolving role of prostate brachytherapy. Cancer Control 2001, 8:163-170
34. Horwitz EM, Hanlon AL, Hanks GE: Update on the treatment of prostate cancer with external beam irradiation. Prostate 1998, 37:195-206
35. Menon M, Shrivastava A, Tewari A: Laparoscopic radical prostatectomy: conventional and robotic. Urology 2005, 66:101-104
36. Miyamoto H, Messing EM, Chang C: Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004, 61:332-353
37. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. J Am Med Assoc 2005, 294:238-244
38. Davidson SD, Cherry JP, Choudhury MS, Tazaki H, Mallouh C, Konno S: Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. J Urol 1999, 161:690-691
39. Davidson SD, Milanesa DM, Mallouh C, Choudhury MS, Tazaki H, Konno S: A possible regulatory role of glyoxalase I in cell viability of human prostate cancer. Urol Res 2002, 30:116-121
40. Antognelli C, Del Buono C, Baldracchini F, Talesa V, Cottini E, Brancadoro C, Zucchi A, Mearini E: Alteration of glyoxalase genes expression in response to testosterone in LNCaP and PC3 human prostate cancer cells. Cancer Biol Ther 2007, 6:1880-1888
41. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, Tsuruo T: Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000, 95:3214-3218
42. Menne TF, Goyenechea B, Sa'nchez-Puig N, Wong CC, Tonkin LM, Ancliff PJ, Brost RL, Costanzo M, Boone C, Warren AJ: The Shwachman-Bodian-Diamond Syndrome protein mediates translational activation of ribosomes in yeast. Nat Genet 2007, 39: 486-495
43. Ganapathi KA, Austin KM, Lee CS, Dias A, Malsch MM, Reed R, Shimamura A: The Human Shwachman-Diamond Syndrome protein, SBDS, associates with ribosomal RNA. Blood 2007, 110:1458-1465
44. Rujkijyanont P, Watanabe K, Ambekar C, Wang H, Schimmer A, Beyene J, Dror Y: SBDS-deficient cells undergo accelerated apoptosis through the Fas pathway. Haematologica 2008, 93:363-371
45. Shwachman H, Diamond LK, Oski FA, Khaw KT: The syndrome of pancreatic insufficiency and bone marrow dysfunction. J Pediatr 1964, 65:645-663
46. Dror Y, Freedman MH: Shwachman-Diamond Syndrome. Br J Haematol 2002, 118:701-713
47. Ginzberg H, Shin J, Ellis L, Morrison J, Ip W, Dror Y, Freedman M, Heitlinger LA, Belt MA, Corey M, Rommens JM, Durie PR: Shwachman Syndrome: phenotypic manifestations of sibling sets and isolated cases in a large patient cohort are similar. J Pediatr 1999, 135:81-88
48. Paulusma CC, Folmer DE, Ho-Mok KS, De Waart DR, Hilarius PM, Verhoeven AJ, Oude Elferink RP: ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology 2008, 47:268-278
49. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ: Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991, 51:3062-3066
50. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C: Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 2002, 277:36570-36576
51. Hu XT, Chen W, Wang D, Shi QL, Zhang FB, Liao YQ, Jin M, He C: The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer. Oncol Rep 2008, 19:441-446
52. Waterham HR, Koster J, Romeijn GJ, Hennekam RC, Vreken P, Andersson HC, Fitzpatrick DR, Kelley RI, Wanders RJ: Mutations in the 3β- hydroxysterol δ24-reductase gene cause desmosterolosis: an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001, 69:685-694
53. Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K: Regulation of cellular response to oncogenic and oxidative stress by seladin-1. Nature 2004, 432:640-645
54. Imperato-Mcginley J, Ip NY, Gautier T, Neuweiler J, Gruenspan H, Liao S, Chang C, Balazs I: DNA linkage analysis and studies of the androgen receptor gene in a large kindred with complete androgen insensitivity. Am J Med Genet 1990, 36:104-108
55. Latulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002, 62:4499-506
56. 2+/calmodulin-dependent protein kinase II promotes cell cycle progression by directly activating MEK1 and subsequently modulating p27 phosphorylation. J Biol Chem 2009, 284:3021-3027
57. Morris TA, Delorenzo RJ, Tombes RM: Camk-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells. Exp Cell Res 1998, 240:218-227
58. Wang C, Li N, Liu X, Zheng Y, Cao X: A novel endogenous human Camkii inhibitory protein suppresses tumor growth by inducing cell cycle arrest via p27 stabilization. J Biol Chem 2008, 283:11565-11574
59. Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, Glover RA, Cohen MB: Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther 2007, 6:732-742
60. Mamaeva OA, Kim J, Feng G, Mcdonald JM: Calcium/calmodul-independent kinase II regulates Notch-1 signaling in prostate cancer cells. J Cell Biochem 2009, 106:25-32
61. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826
62. Elgamal AA, Holmes EH, Su SL, Tino WT, Simmons SJ, Peterson M, Greene TG, Boynton AL, Murphy GP: Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol 2000, 18:10-16
63. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987, 7:927-935
64. Bander NH: Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006, 3:216-225
65. Morey C, Avner P: Employment opportunities for non-coding RNAs. FEBS Lett 2004, 567:27-34
66. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating micrornas as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518
67. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648
68. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J: PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179:1587-1592
69. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006, 52:1089-1095
70. Cho KS, Oh HY, Lee EJ, Hong SJ: Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study. Yonsei Med J 2007, 48:1009-1014
71. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629
72. Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A: Quantitative multigene expression profiling of primary prostate cancer. Prostate 2006, 66:1521-1534